#CitiPharma Ltd. (CPHL) PSX, 1-H chart,Citi Pharma Ltd.PSX_DLY:CPHLMusarrat_karamatTechnical + Structural Recap (on Chart) The chart highlights potential bullish reversal zones built around order blocks, fair value gaps, and a possible demand zone. Price is testing or approaching the lower structure (order blocks / FVG), which may act as a base for a bounce. The trade plan you had: Buy (instant), SL = 93.83, TP1 = 102.36, TP2 = 104.18 is aligned with that idea of catching the next upward leg. The confluence of support zones, volume evidence, and structural price levels gives this setup better odds (though nothing is guaranteed). 📊 Fundamental Backdrop & Ratios Here are key fundamentals and metrics that help validate or challenge the technical view: Revenue & Net Income Recent revenue ~ PKR 12.97B, net income ~ PKR 830.9M Stock Analysis The company is generating meaningful profits; margins matter.P/E Ratio~ 27x (TTM) Dividend Yield~ 3.25% A healthy yield can attract income-focused investors. Share Structure / Market Cap Market cap ~ PKR 22.63B, Paid-up capital ~ PKR 2,284.61M, Free float ~ 50% Decent free float ensures liquidity; mid-cap size means growth potential but also volatility. Subsidiary Launch / New Business Citi’s subsidiary “Citi Veterinary Limited” has started trading operations with 32 veterinary products, and LCs (Letters of Credit) have been established for 8 products. Diversifying into animal health could open new revenue streams. Acquisition InterestCiti Pharma has submitted a non-binding offer for acquisition of a “leading pharmaceutical company” in Pakistan. Profit by Pakistan Today If successful, this can be a catalyst—scale, synergies, expanded product base. 📰 News & Catalysts That Could Push the Share Price Below are some of the latest announcements and potential future catalysts which could drive investor sentiment (and thus price) higher: Subsidiary Launch (Veterinary Business): As mentioned, Citi has formally started operations through its wholly-owned subsidiary in the veterinary products space. This move diversifies revenue and could capture growth in veterinary health demand. Acquisition Bid: The company submitted offers to acquire a major pharmaceutical competitor in Pakistan. If this deal materializes, it could rapidly enhance scale, market share, and product portfolio. Profit by Pakistan Today Profit Surge (in past periods): In Q1 FY25, Citi Pharma’s net profit more than doubled (113.3% jump), largely helped by margin expansion. Flat 9-month Profit: However, for the 9 months ended March 31, 2025, net profit remained nearly flat ~ Rs 678.8M vs prior period, signalling some headwinds. Industry Tailwinds: The pharmaceutical industry in Pakistan is significantly dependent on imports for raw materials (over 90%), which means foreign exchange, import restrictions, or trade relations (especially with India) can hugely affect costs and margins. 🧠Combined Narrative (Tech + Fundamentals + Catalyst) CitiPharma currently sits in a structurally interesting zone on the chart—an order block / fair value gap area that technical traders see as a demand base. The trade plan to buy around there with SL ~ 93.83 and targets near 102–104 is valid if demand holds and the structure doesn’t break. From the fundamental side, the company is showing real growth, with decent margins, a mid-cap scale, and a strategy to expand (via subsidiary and acquisition). The subsidiary in veterinary products is a forward-looking move into a niche but growing market. The acquisition initiative is more speculative, but if it lands, it could spark a re-rating. The ideal bullish scenario is: price respects the support structure, volume picks up to validate a reversal, fundamentals continue to improve (or at least not deteriorate), and any positive news—such as approval of the acquisition, strong earnings beats, or breakthroughs in new product lines—acts as fuel. If price breaks down below SL and structural support, then the bullish view is negated, and deeper downside is possible.